US 11,911,458 B2
HIV pre-immunization and immunotherapy
Charles David Pauza, Rockville, MD (US); Haishan Li, Rockville, MD (US); Tyler Lahusen, Rockville, MD (US); and Gary Mansfield, Rockville, MD (US)
Assigned to American Gene Technologies International Inc., Rockville, MD (US)
Appl. No. 16/312,056
Filed by AMERICAN GENE TECHNOLOGIES INTERNATIONAL INC., Rockville, MD (US)
PCT Filed Jul. 7, 2017, PCT No. PCT/US2017/041168
§ 371(c)(1), (2) Date Dec. 20, 2018,
PCT Pub. No. WO2018/009847, PCT Pub. Date Jan. 11, 2018.
Application 16/312,056 is a continuation in part of application No. PCT/US2017/013019, filed on Jan. 11, 2017.
Claims priority of provisional application 62/409,270, filed on Oct. 17, 2016.
Claims priority of provisional application 62/385,864, filed on Sep. 9, 2016.
Claims priority of provisional application 62/360,185, filed on Jul. 8, 2016.
Prior Publication US 2019/0201523 A1, Jul. 4, 2019
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/12 (2006.01); A61K 31/7105 (2006.01); A61K 35/14 (2015.01); A61K 39/21 (2006.01); A61K 39/39 (2006.01); A61K 45/06 (2006.01); A61K 35/15 (2015.01); A61K 35/17 (2015.01); A61P 31/18 (2006.01); C12N 5/078 (2010.01); C12N 5/0783 (2010.01); C12N 7/00 (2006.01); C12N 15/11 (2006.01); C12N 15/86 (2006.01); C12N 15/113 (2010.01); C07K 14/715 (2006.01); A61K 39/00 (2006.01); A61K 35/12 (2015.01)
CPC A61K 39/21 (2013.01) [A61K 31/7105 (2013.01); A61K 35/14 (2013.01); A61K 39/12 (2013.01); A61K 39/39 (2013.01); A61K 45/06 (2013.01); A61P 31/18 (2018.01); C07K 14/7158 (2013.01); C12N 5/0634 (2013.01); C12N 5/0636 (2013.01); C12N 7/00 (2013.01); C12N 15/111 (2013.01); C12N 15/1132 (2013.01); C12N 15/1138 (2013.01); C12N 15/86 (2013.01); A61K 35/15 (2013.01); A61K 35/17 (2013.01); A61K 2035/124 (2013.01); A61K 2039/5156 (2013.01); A61K 2039/545 (2013.01); A61K 2039/55561 (2013.01); C12N 2310/122 (2013.01); C12N 2310/14 (2013.01); C12N 2310/141 (2013.01); C12N 2320/32 (2013.01); C12N 2330/51 (2013.01); C12N 2510/00 (2013.01); C12N 2710/24143 (2013.01); C12N 2740/15021 (2013.01); C12N 2740/15034 (2013.01); C12N 2740/15043 (2013.01); C12N 2740/15052 (2013.01); C12N 2740/16022 (2013.01); C12N 2740/16034 (2013.01); C12N 2740/16043 (2013.01)] 18 Claims
 
1. A method of treating cells, the method comprising:
(a) positively selecting HIV-specific CD4+ T cells from PBMC isolated from a subject infected with HIV;
(b) contacting the CD4+ T cells with a therapeutically effective amount of a stimulatory agent, wherein the contacting is carried out ex vivo,
wherein the stimulatory agent comprises a peptide, a mixture of peptides, or a vaccine;
(c) transducing the CD4+ T cells ex vivo with a viral delivery system encoding at least one genetic element, wherein the at least one genetic element comprises (i) a sequence having at least 90% sequence identity with SEQ ID NO: 6, (ii) a sequence having at least 90% sequence identity with SEQ ID NO: 7, and (iii) a sequence having at least 90% sequence identity with SEQ ID NO: 97, wherein the at least one genetic element does not comprise any small RNA targeting HIV sequences other than Vif and Tat; and
(d) culturing the transduced CD4+ T cells for at least 1 day.